Agencies, 16 November: Monday te Bharat Biotech Chairman and Managing Director Krishna Ella koise, coronavirus vaccine ‘covaxin’ toh etiya phase-3 trial te jai ase. Indian School of Business para programme organized kora te virtually Ella para koise, company be tusara COVID-19 dawai nemide kaam kori ase. Etu toh nasal drops laga form te hobo aro etu toh aha sal para daiyar hobo.
Krishana Ella koise, Bharat Biotech toh duniya te ekala vaccine company ase BSL3 production facility (Biosafety level 3) thaka te.
Jowa moina etu company koise, vaccine laga Phase 1 aro II trials te interim analysis toh kamiyaab hoikena kothom hoise aro Phase-III trials toh 26,000 participants logode suru kori ase.
Covaxinis toh BharatBiotech para Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV) logode melikena bona laga ase.
City-based vaccine maker para October 2 direk Drug Controller General of India”s (DCGI) ke COVID-19 vaccine laga phase 3 randomised double-blind placebo-controlled multicentre lobo nemide permission lakiya janaideya thakise.
Add Comment